Asthma Exacerbations clinical trials

Explore recruiting asthma exacerbations clinical trials.

Recruiting asthma exacerbations studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Asthma Exacerbations trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants with Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL)

France, Italy, Greece, Spain, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma.

Italy, Belgium, France, Spain, Germany, Poland

Therapeutic use (Phase IV) EU CTIS Study details

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma

Italy, Spain, Czechia, Poland, Germany, Latvia +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Czechia, Spain, Germany, Austria, Lithuania, Hungary +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Asthma Exacerbations trials by city

Asthma Exacerbations clinical trials

Recruiting asthma exacerbations studies right now

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

Azithromycin Treatment of Hospitalized Children With Asthmatic Symptoms

Remote Patient Monitoring Solution for Chronic Respiratory Disease Management

Pollution Intervention to Impact Kids Asthma Study

High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool Children

A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma

Bronchial Thermoplasty for Adults With Severe Asthma in the Biologic Era

Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

Cost Effective Air Filtration Intervention in Low-Income Housing to Reduce Asthma Morbidity

45th Multicenter Airway Research Collaboration

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Also recruiting in Europe

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants with Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL)

A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma.

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

Asthma Exacerbations trials by city

Other conditions